摘要:Objective:To discuss the efficacy and safety of Nifedipine and Nimodipine in the treatment of primary hypertension.Method:100 patients with primary hypertension were randomly divided into the treatment group(n=48) and the control group(n=52),the control group was only given Nifedipine. The treatment group disabled all blood pressure drugs,oral Nifedipine 10 mg,Nimodipine 40 mg,3 times a day.After days of medication,Nifedipine increased to 60 mg a day, Nimodipine increased to 180 mg a day according to blood pressure,15 days later,maintained Nifedipine 30 mg a day,Nimodipine 120 mg a day,4 weeks for a course of treatment.Result:After 4 weeks of treatment,the blood pressure by an average of treatment group (177.0±9.8)/(106.0±9.8)mm Hg decreased to (132.0±9.0)/(90.0±2.3)mm Hg;Blood pressure by an average of the control group (176.0±9.9)/(107.0±9.7)mm Hg decreased to (138.0±9.1)/(95.0±2.2)mm Hg, the total effective rate of treatment group was 95.8%,the control group was 65.4%,the blood pressure and clinical efficacy differences were significant(P<0.05). Also 10 patients with angina pectoris attack stopped,16 patients with ST segment and T wave abnormalities had different degree of recovery,16 cases of ischemic cerebrovascular disease improved obviously in treatment group,control group had 2,8,6 cases respectively,the differences were significant(P<0.05). After treatment,4 cases had facial blushing,4 cases had headache(mainly pain) dizziness,the control group had 7,8 cases respectively.Conclusion:The combination therapy in primary hypertension have a curative effect and synergistic effects on the heart,the blood vessel of brain,and it can improve blood supply of cardiac and cerebral vascular,and can be clinically as ideal antihypertensive drugs for application.%目的:探讨硝苯吡啶与尼莫地平联合治疗原发性高血压的效果及安全性。方法:选取100例原发性高血压患者随机分为治疗组(n=48)和对照组(n=52),对照组单用硝苯吡啶治疗,治疗组全部停用一切可能对血压有影响的药物,口服硝苯吡啶10 mg,尼莫地平40 mg,3次/d。用药数日后,根据血压的情况,硝苯吡啶递增为60 mg/d,尼莫地平递增为180 mg/d,15 d后维持硝苯吡啶30 mg/d,尼莫地平120 mg/d,4周为一疗程。结果:两组患者经4周治疗,治疗组血压由平均(177.0±9.8)/(106.0±9.8)mm Hg下降至(132.0±9.0)/(90.0±2.3)mm Hg;对照组血压由平均(176.0±9.9)/(107.0±9.7)mm Hg下降至(138.0±9.1)/(95.0±2.2)mm Hg。治疗组治疗总有效率为95.8%,对照组为65.4%,两组血压下降程度、临床疗效比较差异均有统计学意义(P<0.05)。同时治疗组中心绞痛患者停止发作10例,心电图ST段和T波异常者均有不同程度的恢复16例,缺血性脑血管病者明显好转16例。对照组分别为2、8、6例,两组比较差异均有统计学意义(P<0.05)。治疗组用药后出现颜面潮红4例,头痛(主要是胀痛)头晕4例,对照组分别为7、8例。结论:两药联合治疗原发性高血压疗效明显,且能协同作用于心、脑血管,改善心、脑血管的供血,临床可以作为理想的降压药物进行临床应用。